Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)

Investigational New Drugs

Volumn 25, Issue 5, 2007, Pages 445-451

  Ryan, Charles J ^a   Stadler, Walter M ^b   Roth, Bruce ^c   Hutcheon, Douglass ^a   Conry, Shauna ^a   Puchalski, Thomas ^d   Morris, Charles ^d   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Angiogenesis inhibitors; Hormone refractory prostate cancer; Pharmacokinetics; Prostate cancer

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; HORMONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTHELIUM CELL; FATIGUE; HUMAN; IN VITRO STUDY; LYMPHADENOPATHY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MUSCLE WEAKNESS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 34547654541     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-007-9050-y     Document Type: Article

References (11)

1. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989
2. Weidner N, Carrol PR, Flax J, et al (1993) Tumor angiogensis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-408
3. Bok RA, Halabi S, Fei DT, et al (2001) Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res 61:2533-2536
4. George DJ, Halabi S, Shepard TF, et al (2001) Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7:1932-1936
5. Huss WJ, Hanrahan CF, Barrios RJ, et al (2001) Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61:2736-2743
6. John V, Mashru S, Lichtman S (2003) Pharmacological factors influencing anticancer drug selection in the elderly. Drugs Aging 20:737-759
7. Wedge SR, Kendrew J, Hennequin LF, et al (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400
8. Bubley GJ, Carducci M, Dahut W, et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-indpendent prostate cancer: recommendations from the PSA Working Group. J Clin Oncol 17:3461-3467
9. Sopher BL, Thomas PS, Jr., LaFevre-Bernt MA, et al (2004) Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 41:687-699
10. Dahut WL, Scripture CD, Posadas EM, et al (2006) Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. pp 450
11. Kelly WK, Scher HI (1993) Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 149:607-609